

REMARKS

The specification has been amended to insert a priority statement, and to make reference to the sequence listing that was filed with the parent application. The application has also been amended to correct the inadvertent omission of the word 'compound' following the word 'oligomeric' on page 11, line 4; this is an obvious clerical error in view of the use of 'oligomeric compound' throughout the specification.

Upon entry of the amendments submitted herewith, claims 1-11, 17, 26, 32, 33, 50 and 51 are currently pending in the instant application. Claims 12-16, 18-25, 27-31, and 34-49 are canceled. Support for the amendments to Claim 1 is found throughout the specification, for example, page 14, lines 23-27; page 127, column 4 of table 7; and page 10, line 2. Support for the amendments to Claim 32 is found throughout the specification, for example, page 32, lines 22-30. Claims 50 and 51 are newly introduced and are supported throughout the specification, for example, in the original claims and on page 33, respectively. The Applicants submit that no new matter is added by these amendments.

The Applicants respectfully request that the cancellation of claims and amendments to the claims be made prior to calculation of the filing fees.

FEEES


It is believed that no fee is due with this amendment. However, if a fee is due, the Commissioner is hereby authorized to charge the Deposit Account 50-0252 referencing case number ISPH-0595USA.

CONCLUSIONS

In view of these amendments and remarks, the Applicants believe that the case is now in proper form for examination. A prompt office action on the merits of the case is requested.

Respectfully submitted,

Dated: Dec 2 2005



Frances R. Putkey, Ph.D.
Agent for Applicant
Registration No. 57,257

Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008
Telephone: (760) 931-9200
Facsimile: (760) 603-3820